Table 2.
Mechanisms of anticancer action of SGLT-2 inhibitors.
| Cancer Type | Type of SGLT-2 Inhibitor Drug | Mechanism of Action |
|---|---|---|
| Hepatocellular carcinoma (HCC) | Canagliflozin | Inhibition of the action of β-catenin |
| HCC, prostate cancer, lung cancer, liver cancer and breast cancer | Canagliflozin | Inhibition of complex I and subunit α of ATP synthase F1 in the mitochondrial electron transport chain |
| Breast cancer, HCC | Canagliflozin | Suppression of SREBP1 and SCD1 |
| HCC | Canagliflozin | Cell cycle arrest |
| Breast cancer, pancreatic cancer | Canagliflozin | Inhibition of mTOR |
| HCC | Canagliflozin | Inhibition of DNA and RNA synthesis |
| HCC | Canagliflozin | Induction of G2/M arrest and inhibition of proangiogenic factors |
| Breast cancer | Ipragliflozin | Inhibition of cellular sodium influx |
| Breast cancer | Canagliflozin | Disruption of glutamine metabolism |
| Lung cancer | Canagliflozin | Inhibition of L858R/T790M EGFR kinase |
| Human colon carcinoma | Dapagliflozin | Reduction in the adhesion of cancer cells |